Much further work is required in large, multi-centre studies by independent research groups if robust biomarkers for prostate cancer are ever to be found considering the past failures to corroborate initially “promising” biomarkers, with PSA and sarcosine being prime examples. This evidence concerns the gene KLK3 and prostate carcinoma.